“Critical Path” Is On The Road Forward; FDA Reports Industry Activity Is High
Executive Summary
The Critical Path Initiative is entering 2007 with growing momentum, bolstered by a new, tailored agency infrastructure and increased industry awareness of FDA's initiative to spur drug development
You may also be interested in...
Biomarkers For Alzheimer's, Parkinson's Disease To Be Developed By Industry Coalition Through First-Of-A-Kind Clinical Data Exchange
Unable to defeat Alzheimer's Disease and Parkinson's Disease, companies have joined forces to come up with new research tools
Biomarkers For Alzheimer's, Parkinson's Disease To Be Developed By Industry Coalition Through First-Of-A-Kind Clinical Data Exchange
Unable to defeat Alzheimer's Disease and Parkinson's Disease, companies have joined forces to come up with new research tools
Serious Adverse Events Consortium Expects Data On Genetic Variants Shortly
Initial data generated by the Serious Adverse Events Consortium with regard to DNA variants associated with drug-related serious skin rash will be available at the end of 2008 or in January 2009, SAEC executive director Arthur Holden predicts